Eupraxia Pharmaceuticals Inc
TSX:EPRX
Eupraxia Pharmaceuticals Inc
Operating Income
Eupraxia Pharmaceuticals Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Operating Income
-CA$27.4m
|
CAGR 3-Years
-126%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Zymeworks Inc
NYSE:ZYME
|
Operating Income
-$138.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Operating Income
-$116.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Operating Income
-$99.2m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Operating Income
-$91.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-36%
|
|
Spectral Medical Inc
TSX:EDT
|
Operating Income
-CA$11.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
0%
|
See Also
What is Eupraxia Pharmaceuticals Inc's Operating Income?
Operating Income
-27.4m
CAD
Based on the financial report for Dec 31, 2023, Eupraxia Pharmaceuticals Inc's Operating Income amounts to -27.4m CAD.
What is Eupraxia Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-18%
Over the last year, the Operating Income growth was -20%. The average annual Operating Income growth rates for Eupraxia Pharmaceuticals Inc have been -126% over the past three years , -18% over the past five years .